Development and validation of a mutation-annotated prognostic score for intrahepatic cholangiocarcinoma after resection: a retrospective cohort study
Open Access
- 11 August 2023
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (11) , 3506-3518
Abstract
Background: The value of existing prognostic models for intrahepatic cholangiocarcinoma is limited. The inclusion of prognostic gene mutations would enhance the predictive efficacy. Methods: In the screening cohorts, univariable Cox regression analysis was applied to investigate the effect of individual mutant genes on overall survival (OS). In the training set, multivariable analysis was performed to evaluate the independent prognostic roles of the clinicopathological and mutational parameters, and a prognostic model was constructed. Internal and external validations were conducted to evaluate the performance of this model. Results: Among the recurrent mutations, only TP53 and KRAS G12 were significantly associated with OS across all three screening cohorts. In the training cohort, TP53 and KRAS G12 mutations in combination with seven other clinical parameters (tumor size, tumor number, vascular invasion, lymph node metastasis, adjacent invasion, CA19-9, and CEA), were independent prognostic factors for OS. A mutation-annotated prognostic score (MAPS) was established based on the nine prognosticators. The C-indices of MAPS (0.782 and 0.731 in the internal and external validation cohorts, respectively) were statistically higher than those of other existing models (P<0.05). Furthermore, the MAPS model also demonstrated significant value in predicting the possible benefits of upfront surgery and adjuvant therapy. Conclusions: The MAPS model demonstrated good performance in predicting the OS of intrahepatic cholangiocarcinoma patients. It may also help predict the possible benefits of upfront surgery and adjuvant therapy.Keywords
This publication has 77 references indexed in Scilit:
- Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different OutcomesGastroenterology, 2013
- Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase InhibitorsGastroenterology, 2012
- Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinomaHepatology, 2011
- Staging of Peripheral‐Type Intrahepatic Cholangiocarcinoma: Appraisal of the New TNM Classification and its ModificationsWorld Journal of Surgery, 2011
- A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan scoreAnnals of Oncology, 2011
- AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinomaCancer, 2010
- A Proposed Staging System for Intrahepatic CholangiocarcinomaAnnals of Surgical Oncology, 2009
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005
- Intrahepatic cholangiocarcinoma: macroscopic type and stage classificationJournal of Hepato-Biliary-Pancreatic Surgery, 2003
- A new staging system for mass-forming intrahepatic cholangiocarcinomaCancer, 2001